A selective alpha-4-beta-2 ligand for the treatment of major depressive disorders (MDD). SUVN-911 has excellent antidepressant properties with rapid onset of action, devoid of sexual dysfunction, weight gain or cognitive dulling. SUVN-911 has good ADME properties, excellent safety profile, completed all the preclinical studies and early tox studies. GLP tox studies are in progress prior to filing of US-IND for initiation into Phase 1 trial in USA